Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $25.25 Consensus PT from Brokerages


Share on StockTwits

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) have earned a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $25.25.

Several analysts recently commented on the company. SVB Leerink raised their price objective on Xenon Pharmaceuticals from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Monday, March 8th. Zacks Investment Research downgraded Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. William Blair reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Friday, March 5th. Finally, Needham & Company LLC raised their price objective on Xenon Pharmaceuticals from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, March 8th.

Shares of XENE stock traded down $0.28 during trading hours on Tuesday, reaching $18.35. The company had a trading volume of 93,042 shares, compared to its average volume of 183,065. The company has a 50 day moving average of $18.44 and a 200 day moving average of $15.19. The firm has a market cap of $751.67 million, a price-to-earnings ratio of -18.92 and a beta of 1.20. Xenon Pharmaceuticals has a 1-year low of $9.32 and a 1-year high of $21.94.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Monday, March 1st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.06. The company had revenue of $5.15 million for the quarter, compared to the consensus estimate of $3.50 million. Xenon Pharmaceuticals had a negative return on equity of 21.76% and a negative net margin of 102.25%. On average, equities analysts predict that Xenon Pharmaceuticals will post -0.87 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Xenon Pharmaceuticals during the 1st quarter worth about $73,000. Accel Wealth Management bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $138,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $158,000. DekaBank Deutsche Girozentrale bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $157,000. Finally, LPL Financial LLC bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $204,000. Hedge funds and other institutional investors own 79.90% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

Featured Story: Conference Calls and Individual Investors

Analyst Recommendations for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.